Welcome to our dedicated page for Solventum SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Solventum's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Solventum's regulatory disclosures and financial reporting.
Solventum Corp director Carrie Smith Cox exercised restricted stock units into common shares. On March 27, 2026, she exercised 6,336 Restricted Stock Units, each representing one share of common stock upon settlement. Following the exercise, she directly holds 11,484 shares of Solventum common stock. The filing states the RSUs were fully vested at the time of exercise.
Solventum Corp director Susan D. DeVore exercised fully vested Restricted Stock Units to receive Common Stock as equity compensation. She converted 1,980 RSUs, each representing a contingent right to one share of Common Stock, into 1,980 shares at an exercise price of $0.00 per share.
After the transaction, she directly holds 5,544 shares of Solventum Common Stock. The filing shows a routine derivative exercise/conversion with no open‑market buying or selling activity.
Solventum Corp director Shirley Ann Edwards exercised restricted stock units into common shares. On March 27, 2026, she converted 1,980 Restricted Stock Units, each representing a right to receive one share of common stock when settled. This derivative exercise resulted in 1,980 shares of Solventum common stock credited to her direct holdings.
Following the transaction, Edwards directly holds 5,544 shares of Solventum common stock. The filing describes this as an exercise or conversion of a derivative security, not an open-market purchase or sale, and the RSUs involved were reported as fully vested.
Solventum Corp director Glenn A. Eisenberg exercised equity awards to increase his direct share ownership. He converted 1,980 fully vested Restricted Stock Units into 1,980 shares of Common Stock at no exercise price. Following the transaction, he directly holds 5,544 Solventum common shares. This was an option/RSU exercise, not an open-market purchase or sale.
Solventum Corp director Harris Bernard A Jr exercised previously granted Restricted Stock Units, converting 1,980 RSUs into 1,980 shares of Common Stock at a stated price of $0.00 per share. Following this vesting and settlement event, he now directly holds 5,544 shares of Solventum Common Stock. The RSUs were fully vested before settlement, meaning the shares were delivered as part of his existing equity compensation rather than through an open-market purchase or sale.
Solventum Corp director Wilson Darryl L. exercised restricted stock units into common shares. He converted 1,980 Restricted Stock Units into 1,980 shares of Common Stock at a stated price of $0.00 per share, reflecting settlement of fully vested RSUs. Following the transaction, he directly holds 5,544 shares of Solventum common stock.
Solventum Corp director Wendell Amy McBride exercised fully vested Restricted Stock Units into common stock. McBride converted 1,980 RSUs, each representing one share of common stock, at an exercise price of $0.00 per unit. Following the transaction, McBride directly holds 7,019 shares of Solventum common stock. This filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale.
Solventum Corp director John H. Weiland exercised equity awards rather than trading in the open market. On March 27, 2026, he exercised 1,980 Restricted Stock Units, each converting into one share of Solventum common stock at a stated price of $0.00 per share.
Following this RSU settlement, Weiland now directly holds 5,544 shares of Solventum common stock. The filing shows no open-market purchases or sales, only the conversion of fully vested RSUs into common shares as part of his equity compensation.
Solventum Corp director Mily Elizabeth exercised fully vested restricted stock units to receive common shares. On March 27, 2026, she exercised 1,980 RSUs, each representing one share of common stock, at an exercise price of $0.00 per unit.
Following the conversion, she directly holds 5,606 shares of Solventum common stock. The RSU award is now fully settled with no RSUs remaining outstanding from this grant, and there were no open-market purchases or sales reported in this filing.
Solventum Corp director Carlos Alban exercised restricted stock units to receive common shares. On this date, he converted 1,980 fully vested RSUs into 1,980 shares of Solventum common stock at an exercise price of $0.00 per unit. After the transaction, he holds 5,544 common shares directly.